Secondary hyperparathyroidism and its therapy as a cardiovascular risk factor among end-stage renal disease patients.

Coladonato JA; Ritz E

首页> 外文期刊>Advances in renal replacement therapy >Secondary hyperparathyroidism and its therapy as a cardiovascular risk factor among end-stage renal disease patients.

【24h】

Secondary hyperparathyroidism and its therapy as a cardiovascular risk factor among end-stage renal disease patients.

机译：继发性甲状旁腺功能亢进及其作为终末期肾病患者心血管疾病危险因素的治疗。

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Secondary hyperparathyroidism (HPTH) was initially viewed as a disorder of the skeletal system; however, recent population-based data have associated markers of HPTH with an increased cardiovascular mortality among patients with end-stage renal disease (ESRD). This has stimulated much interest in further evaluating secondary HPTH as a cardiovascular disease risk factor, as well as the putative role of its therapy. This article explores the current state of scientific evidence concerning the pathophysiology of cardiovascular disease among the ESRD population and potential risk factors for its development, including markers of HPTH, and its therapies.

机译：继发性甲状旁腺功能亢进症（HPTH）最初被认为是骨骼系统疾病。然而，最近的基于人群的数据将HPTH标记物与患有终末期肾病（ESRD）的患者的心血管死亡率增加相关联。这引起了人们对进一步评估继发性HPTH作为心血管疾病危险因素及其治疗的假定作用的浓厚兴趣。本文探讨了有关ESRD人群中心血管疾病的病理生理学及其发展的潜在危险因素（包括HPTH标记及其疗法）的科学证据的现状。

著录项

来源
《Advances in renal replacement therapy》 |2002年第3期|共7页
作者
Coladonato JA; Ritz E;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类泌尿科学（泌尿生殖系疾病）;
关键词
Cardiovascular; Therapeutic procedure; Risk Factors; Diagnostic Neoplasm Staging; 危险因素; 肾疾病;

机译：Cardiovascular;Therapeutic procedure;Risk Factors;Diagnostic Neoplasm Staging;危险因素;肾疾病;

相似文献

外文文献
中文文献
专利

1. Secondary hyperparathyroidism and its therapy as a cardiovascular risk factor among end-stage renal disease patients. [J] . Coladonato JA, Ritz E Advances in renal replacement therapy . 2002,第3期

机译：继发性甲状旁腺功能亢进及其作为终末期肾病患者心血管疾病危险因素的治疗。
2. Complement factor H gene polymorphism and risk of cardiovascular disease in end-stage renal disease patients. [J] . Buraczynska M, Ksiazek P, Zukowski P Clinical immunology: The official journal of the Clinical Immunology Society . 2009,第2期

机译：补充因子H基因多态性与终末期肾脏疾病患者的心血管疾病风险。
3. Bpd ates Cardiovascular risk factors and cardiovascular disease in patients with type 1 diabetes and end-stage renal disease candidates for kidney-pancreas transplantation: Trends from 1999 to 2017 [J] . Diabetes research and clinical practice . 2020,第期

机译：BPD患有1型糖尿病患者的心血管危险因素和心血管疾病，肾胰腺末期肾病候选者：1999年至2017年的趋势
4. Non-Traditional Cardiovascular Disease Risk Factors and Arterial Inflammatory Response in End-Stage Renal Disease [C] . Tomris Ozben North Atlantic Treaty Organization Advanced Study Institute. meeting . 2003

机译：非传统心血管疾病危险因素及末期肾病中的动脉炎症反应
5. Pharmacogenetics of Rosuvastatin Therapy and Genetic Determinants of Some Cardiovascular Risk Factors in Chinese Patients. [D] . Hu, Miao. 2010

机译：瑞舒伐他汀治疗的药物遗传学和一些心血管疾病危险因素的遗传决定因素。
6. The association of secondary hyperparathyroidism and myocardial damages in hemodialysis end-stage renal disease patients: assessed by cardiovascular magnetic resonance native T1 mapping [O] . Huayan Xu, Wanlin Peng, Zhigang Yang, 2021

机译：继发甲状旁腺功能亢进和心肌损伤的关联血液透析末期肾病患者：通过心血管磁共振天然T1测绘评估
7. P1246Age-, body size-, and sex-specific reference values for tricuspid valve apparatus parameters by real-time three-dimensional transthoracic echocardiographyP1247Surgical therapy in infective endocarditis: predisposing and prognostic factorsP1248Evalutation of MV annulus geometry modifications before and after mitraclip implantation with 3D transesophageal echocardiographyP1249Prognostic echocardiographic parameters for successful transcatheter edge-to-edge mitral valve repairP1250Influence of body surface area in diagnosis and outcome patient-prosthesis mismatch after TAVI. Is it necessary to adjust for ideal body weight?P1251Outcome of paradoxical low-flow low-gradient severe AS following TAVI: paradoxical VS parallel to outcome of high gradient ASP1252Prognostic role of cardiac calcifications in subjects without overt significant heart disease and previous cardiovascular events: is there an additive value over cardiovascular risk factors scores?P1253Aging degeneration of mitral valve without leaflet prolapse or tethering as a cause of severe mitral regurgitationP1254Cardiovascular risk assessment should be performed in patients with incidental aortic sclerosisP1255Cardiac valve calcification score: simple 2D echocardiographic tool for cardiovascular risk stratification in patients with chronic renal failureP1256Diastolic mitral regurgitation following transcatheter aortic valve replacement: prevalence, predictors and impact on outcomesP1257Timing of myocardial shortening determines left ventricular regional remodelling in hearts with conduction delaysP1258Myocardial stiffness assessment using shear wave imaging in healthy children and hypertrophic cardiomyopathyP1259Assessment of right ventricular response to exercise using vector velocity imaging in hypertrophic cardiomyopathyP1260Diagnostic value of cardiac biomarkers (high sensitive troponin T and N-terminal pro-brain natriuretic peptide) in patients with infiltrative cardiomyopathiesP1261Right ventricular global longitudinal strain differentiates between adolescent patients with definite, borderline and possible ARVC and controlsP1262 echogrqphic predictif factors of atrial arrhythmias in patients with arrhythmogenic right ventricular dysplasiaP1263Importance of combined left atrial size and estimated pulmonary pressure for clinical outcome in patients presenting with heart failure with preserved ejection fractionP1264Chronotropic response in mitochondrial (ANT1) cardiomyopathyP1265 The effect of cardiovascular risk factors and cancer type in anthracycline's cardiotoxicityP1266Revisiting the echocardiographic features of acute myocarditisP1267Altered circulation in fetuses of diabetic mothers: a fetal computational model analysisP1268Increased epicardial adipose tissue is related to stress-induced cardiomyopathyP1269Contrast enhanced ultrasound of kidney perfusion in patients with renal artery stenosis: diagnostic and prognostic applications. [O] . F. Ancona, R. Ilhao Moreira, V. Lavanco, 2016

机译：P1246age-，身体大小和性别特异性参考Tricuspid阀装置参数通过实时三维经线性超声心动图124772777777747774747478EVALIGUTALMEXP1249预期植入前后MV环形植入前后MV环空性修饰。超声心动图参数用于成功的经截管边缘到边缘二尖瓣修复P1250中的体表面积诊断和结果患者假体在Tavi后的不匹配。是否有必要调整理想的体重？P1251矛盾的低流量低梯度严重，如Tavi：矛盾的VS平行于高梯度ASP1252的结果，在没有明显显着的心脏病和以前心血管事件的情况下心脏钙化的促傲作用患有心血管危险因素的添加剂值分数？没有传单脱垂的二尖瓣退化或作为严重二尖瓣血管血管血管病风险评估的患者进行脱垂或系绳，应当在偶然主动脉源肺源P1255Cariac阀钙化评分患者中进行：用于心血管风险分层的简单2D超声心动图工具在慢性肾功能衰竭的患者中，经沟管主动脉瓣膜置换术后：流行率，预测因子和对Otcomasp1257的影响，心肌缩短决定了导通延迟的心中的剩余心室区域重新耦合258MYCIARIAL僵硬评估使用剪切波成像在健康儿童和肥厚性心肌脑病中的舒缓性心脏响应，在渗透心肌肌瘤患者中使用载体速度成像的培养速度成像（高敏感的肌钙蛋白T和N-末端脑Natrietic肽）渗透心肌病，患者心室全局纵向菌株在患有心律失常右心室发育不良患者的心理心律失常患者中的青少年患者与Controlsp1262 echogrqphic预测因子的分歧，患者心血性右心室发育不良患者患者患者患者患者患者患者患者患者患者线粒体（ANT1）心肌病患者的喷射FRACTIONP1264系列响应1265心血管危险因素和癌症类型在蒽丙烯的心肌毒性皮1126660中的影响访问患有糖尿病母亲胎儿胎儿急性心肌炎的超声心动图，患者患者：胎儿计算模型分析P1268增加外膜脂肪组织与肾动脉狭窄患者肾脏灌注的应激诱导的心肌病，增强超声波：诊断和预后应用。

Secondary hyperparathyroidism and its therapy as a cardiovascular risk factor among end-stage renal disease patients.

摘要

著录项

相似文献

相关主题

期刊订阅